Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202405130 A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with Solid Tumors (eVOLVE-01) New Drug Phase Ⅱ
N202406028 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Systemic Lupus Erythematosus New Drug Phase Ⅱ
N202406041 A Clinical Trial to evaluate the Safety and Efficacy of Microtube Array Membrane (MTAM)-Encapsulated Cell Therapy of Mesenchymal Stem Cells for Treatment of Alzheimer’s Disease New Medical Device NA
N202406043 A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma New Drug Phase Ⅱ
N202406051 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants with Chronic Rhinosinusitis with Nasal Polyps on Background Intranasal Corticosteroids New Drug Phase Ⅲ
N202407037 A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy who have completed a Novartis-sponsored iptacopan parent study in IgAN New Drug Phase Ⅲ
N202407069 Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO) New Drug Phase Ⅲ
N202407075 A Phase 3, Multicenter, Randomized, Open Label Study Of Ifinatamab Deruxtecan (I-DXd), A B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment Of Physician’s Choice (TPC) In Subjects With Relapsed Small Cell Lung Cancer (SCLC)(IDeate-Lung02) New Drug Phase Ⅲ
1 2 17 18 19 20 21 22 23 51 52 / 52

TOP